Proteoglycans on bone tumor development

Drug Discovery Today

Volumn 15, Issue 13-14, 2010, Pages 553-560

  Velasco, Carmen Ruiz ^a,b   Colliec Jouault, Sylvia ^c   Redini, Françoise ^a,b   Heymann, Dominique ^a,b,d   Padrines, Marc ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b Universite de Nantes   (France)

^c IFREMER   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; BIGLYCAN; CHONDROITIN SULFATE; DECORIN; DERMATAN SULFATE; FIBROMODULIN; GLYPICAN 3; HEPARAN SULFATE; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KERATAN SULFATE; OSTEOPROTEGERIN; PERLECAN; PROTEOGLYCAN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; VERSICAN;

BONE METASTASIS; BONE TUMOR; CELL DIFFERENTIATION; CELL PROLIFERATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; REVIEW; TUMOR GROWTH;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; CELL PROLIFERATION; DRUG DESIGN; HUMANS; PROTEOGLYCANS;

EID: 77954312923     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.05.009     Document Type: Review

References (60)

1. Ruoslahti E. Structure and biology of proteoglycans. Annu. Rev. Cell Biol. 1988, 4:229-255.
2. Bernfield M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
3. Lamoureux F., et al. Proteoglycans: key partners in bone cell biology. Bioessays 2007, 29:758-771.
4. Baud'huin M., et al. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev. Anticancer Ther. 2007, 7:221-232.
5. Théoleyre S., et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK. Biochem. Biophys. Res. Commun. 2006, 347:460-467.
6. Standal T., et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002, 100:3002-3007.
7. Mosheimer B.A., et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J. Clin. Endocrinol. Metab. 2005, 90:2964-2971.
8. Tat S.K., et al. OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 2006, 39:706-715.
9. Kram V., et al. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J. Cell. Physiol. 2006, 207:784-792.
10. Ariyoshi W., et al. Heparin inhibits osteoclastic differentiation and function. J. Cell. Biochem. 2008, 103:1707-1717.
11. Irie A., et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007, 41:165-174.
12. Walton K.J., et al. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 2002, 100:2530-2536.
13. Rajgopal R., et al. The effects of heparin and low molecular weight heparins on bone. Thromb. Res. 2008, 122:293-298.
14. Li Z., et al. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J. Biol. Chem. 2002, 277:28669-28676.
15. Ra H.J., et al. Control of promatrilysin (MMP7) activation and substrate-specific activity by sulfated glycosaminoglycans. J. Biol. Chem. 2009, 284:27924-27932.
16. Crabbe T., et al. Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur. J. Biochem. 1993, 218:431-438.
17. Echtermeyer F., et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat. Med. 2009, 15:1072-1076.
18. Munesue S., et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J. Biol. Chem. 2007, 282:28164-28174.
19. Sørensen H.P., et al. Heparan sulfate regulates ADAM12 through a molecular switch mechanism. J. Biol. Chem. 2008, 283:31920-31932.
20. Bi Y., et al. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone 2006, 38:778-786.
21. Nikitovic D., et al. Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res. 2005, 25:2851-2856.
22. Haupt L.M., et al. The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. J. Cell. Physiol. 2009, 220:780-791.
23. Teplyuk N.M., et al. The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts. J. Cell. Biochem. 2009, 107:144-154.
24. Kumarasuriyar A., et al. De-sulfation of MG-63 cell glycosaminoglycans delays in vitro osteogenesis, up-regulates cholesterol synthesis and disrupts cell cycle and the actin cytoskeleton. J. Cell. Physiol. 2009, 219:572-583.
25. Manton K.J., et al. Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 2007, 25:2845-2854.
26. Miyazaki T., et al. Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J. Cell. Physiol. 2008, 217:769-777.
27. Kanzaki S., et al. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J. Cell. Physiol. 2008, 216:844-850.
28. Zhao B., et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J. Biol. Chem. 2006, 281:23246-23253.
29. Jiao X., et al. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J. Biol. Chem. 2007, 282:1080-1086.
30. Manton K.J., et al. Bone-specific heparan sulfates induce osteoblast growth arrest and downregulation of retinoblastoma protein. J. Cell. Physiol. 2006, 209:219-229.
31. Fjeldstad K., Kolset S.O. Decreasing the metastatic potential in cancers-targeting the heparan sulfate proteoglycans. Curr. Drug Targets 2005, 6:665-682.
32. Sanderson R.D. Heparan sulfate proteoglycans in invasion and metastasis. Semin. Cell Dev. Biol. 2001, 12:89-98.
33. Couchman J.R., Woods A. Syndecan-4 and integrins: combinatorial signaling in cell adhesion. J. Cell Sci. 1999, 112:3415-3420.
34. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
35. Araki K., et al. DEcoRIn suppresses bone metastasis in a breast cancer cell line. Oncology 2009, 77:92-99.
36. Zafiropoulos A., et al. DEcoRIn-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol. Cancer Res. 2008, 6:785-794.
37. Grant D.S., et al. DEcoRIn suppresses tumor cell-mediated angiogenesis. Oncogene 2002, 21:4765-4777.
38. Lamoureux F., et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res. 2009, 69:526-536.
39. Nikolova V., et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30:397-407.
40. Yamada S., Sugahara K. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr. Drug Discov. Technol. 2008, 5:289-301.
41. Malavaki C., et al. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect. Tissue Res. 2008, 49:133-139.
42. Jonca F., et al. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J. Biol. Chem. 1997, 272:24203-24209.
43. Liu L., et al. Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides. Bioorg. Med. Chem. Lett. 2008, 18:344-349.
44. Zhou Y., et al. Heparanase promotes bone destruction and invasiveness in prostate cancer. Cancer Lett. 2008, 268:252-259.
45. Purushothaman A., et al. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 2008, 283:32628-32636.
46. Parish C.R., et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999, 59:3433-3441.
47. Ferro V., et al. Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC. Carbohydr. Res. 2002, 337:139-146.
48. Kudchadkar R., et al. PI-88: a novel inhibitor of angiogenesis. Expert Opin. Investig. Drugs 2008, 17:1769-1776.
49. Basche M., et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin. Cancer Res. 2006, 12:5471-5480.
50. Lewis K.D., et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest. New Drugs 2008, 26:89-94.
51. Francis D.J., et al. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ. Res. 2003, 92:e70-e77.
52. Brown A.J., et al. Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone 2008, 43:689-699.
53. Mayer A.M., Lehmann V.K. Marine pharmacology in 1999: antitumor and cytotoxic compounds. Anticancer Res. 2001, 21:2489-2500.
54. Guezennec J. Deep-sea hydrothermal vents: a new source of innovative bacterial exopolysaccharides of biotechnological interest?. J. Ind. Microbiol. Biotechnol. 2002, 29:204-208.
55. Alban S., et al. PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. J. Invest. Dermatol. 2009, 129:1192-1202.
56. Alban S., et al. A concert of actions contributes to the antimetastastic activity of the semisynthetic glucan sulfate PS3. Haematol. Rep. 2005, 1:74.
57. Zhao H., et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006, 66:8779-8787.
58. Li Q.N., et al. Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells. Acta Pharmacol. Sin. 2009, 30:1033-1038.
59. Sawai H., et al. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol. Cancer 2005, 4:37.
60. Groth I., et al. Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides-comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. Glycobiology 2009, 19:408-417.